RaQualia Pharma Inc. (TSE:4579) agreed to acquire FIMECS, Inc. from Yusuke Tominari, Kamakanae, Nissay Capital No. 11 Investment Limited Partnership managed by Nissay Capital Co., Ltd., ANRI No. 4 Fund managed by ANRI and others for ¥4.5 billion on February 14, 2024. FIMECS reported net worth of ¥625 million, total assets of ¥848 million, operating Loss of ¥576 million and net loss of ¥567 million as at December 2023. The transaction is expected to close on March 26, 2024.

RaQualia Pharma Inc. (TSE:4579) completed the acquisition of FIMECS, Inc. from Yusuke Tominari, Kamakanae, Nissay Capital No. 11 Investment Limited Partnership managed by Nissay Capital Co., Ltd., ANRI No. 4 Fund managed by ANRI and others on March 26, 2024.